Autoimmune hepatitis: an approach to disease understanding and management.

INTRODUCTION Autoimmune hepatitis is a chronic immune-mediated liver injury, frequently associated with progression to end-stage liver disease if untreated. Patients commonly present with hepatitis, positive immune serology, elevated immunoglobulins and compatible liver histology, in the absence of an alternative aetiology. SOURCES OF DATA Data for this review were obtained using PubMed. AREAS OF AGREEMENT Disease usually responds to steroids and azathioprine, and appears to be a manifestation of autoimmune predisposition triggered in genetically susceptible individuals exposed to likely environmental challenges. We provide an up-to-date approach to disease understanding and management along with the clinical approach to diagnosis and current treatment suggestions. AREAS OF CONTROVERSY Controversies such as second line therapies and novel markers of disease activity are introduced. GROWING POINTS Increased understanding of the immunoregulatory mechanisms behind autoimmune hepatitis has led to opportunities for new therapies. These are developed including a discussion of timely research studies relevant to future therapies for patients.

[1]  S. Pocock,et al.  Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. , 1980, Gut.

[2]  A. Lohse,et al.  Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. , 2015, Journal of hepatology.

[3]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[4]  C. Weston,et al.  Distinct Roles for CCR4 and CXCR3 in the Recruitment and Positioning of Regulatory T Cells in the Inflamed Human Liver , 2010, The Journal of Immunology.

[5]  A. Quaas,et al.  Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. , 2013, Journal of hepatology.

[6]  B. Aqel,et al.  Efficacy of Tacrolimus in the Treatment of Steroid Refractory Autoimmune Hepatitis , 2004, Journal of clinical gastroenterology.

[7]  M. Hussain,et al.  Autoantigen‐specific regulatory T cells, a potential tool for immune‐tolerance reconstitution in type‐2 autoimmune hepatitis , 2011, Hepatology.

[8]  K. Boberg,et al.  Simplified criteria for the diagnosis of autoimmune hepatitis , 2008, Hepatology.

[9]  M. Manns,et al.  Diagnosis and management of autoimmune hepatitis , 2010, Hepatology.

[10]  D. Vergani,et al.  Dysfunctional CD39POS regulatory T cells and aberrant control of T‐helper type 17 cells in autoimmune hepatitis , 2014, Hepatology.

[11]  A. Zhernakova,et al.  Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. , 2014, Gastroenterology.

[12]  D. Vergani,et al.  Autoimmune hepatitis in children: what is different from adult AIH? , 2009, Seminars in liver disease.

[13]  M. Manns,et al.  Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. , 2010, Gastroenterology.

[14]  Rodrigo Liberal,et al.  Inhibition of interleukin-17 promotes differentiation of CD25⁻ cells into stable T regulatory cells in patients with autoimmune hepatitis. , 2012, Gastroenterology.

[15]  Roger Williams,et al.  Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal , 1988, Hepatology.

[16]  R. Stern,et al.  Controlled trial of prednisone and azathioprine in active chronic hepatitis. , 1973, Lancet.

[17]  C. Coffin,et al.  Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. , 2013, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[18]  M. Campbell,et al.  Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. , 2011, Gastroenterology.

[19]  M. Manns,et al.  International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. , 1999, Journal of hepatology.

[20]  M. Heneghan,et al.  British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis , 2011, Gut.

[21]  A. Czaja Review article: permanent drug withdrawal is desirable and achievable for autoimmune hepatitis , 2014, Alimentary pharmacology & therapeutics.

[22]  A. Lohse,et al.  Autoimmune hepatitis: a life-long disease. , 2013, Journal of hepatology.

[23]  D. Vergani,et al.  Autoimmune hepatitis: Contrasts and comparisons in children and adults - a comprehensive review. , 2013, Journal of autoimmunity.

[24]  M. Walsh,et al.  Medullary thymic epithelial cell depletion leads to autoimmune hepatitis. , 2013, The Journal of clinical investigation.

[25]  P. Galle,et al.  Mycophenolate Mofetil as Second Line Therapy in Autoimmune Hepatitis? , 2008, The American Journal of Gastroenterology.

[26]  D. Adams,et al.  Regulatory T cells and autoimmune hepatitis: what happens in the liver stays in the liver. , 2014, Journal of hepatology.

[27]  B. Portmann,et al.  Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. , 2008, Journal of hepatology.

[28]  P. Galle,et al.  Concurrent Autoimmune Diseases in Patients With Autoimmune Hepatitis , 2010, Journal of clinical gastroenterology.

[29]  O. Chazouilleres,et al.  Primary biliary cirrhosis–autoimmune hepatitis overlap syndrome: Clinical features and response to therapy , 1998, Hepatology.

[30]  L. Lennard,et al.  Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis , 2012, Hepatology.

[31]  K. Sherman,et al.  Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. , 1994, Journal of hepatology.